The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Open accessAbstract
Key Points: A heteroclitic WT1 peptide vaccine is well tolerated and induces immunologic responses in most acute myeloid leukemia patients post-CR1. Median overall survival for the group of patients vaccinated was not reached but is poised to reach or exceed 67.6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Cited by
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
Peptide‐based therapeutic cancer vaccine: Current trends in clinical application
Liu, W., Tang, H., Li, L., Wang, X., Yu, Z., & Li, J. (2021) · Cell Proliferation · doi:10.1111/cpr.13025 · Cited by 200
Metadata
- Authors
- Maslak, P. G., Dao, T., Bernal, Y., Chanel, S. M., Zhang, R., Frattini, M., Rosenblat, T., Jurcic, J. G., Brentjens, R. J., Arcila, M. E., Rampal, R., Park, J. H., Douer, D., Katz, L., Sarlis, N., Tallman, M. S., & Scheinberg, D. A.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2018-01-31
- Volume
- 2
- Issue
- 3
- Pages
- 224-234
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W2788365551
- Cited by
- 161
- References
- 1
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2017014175
- The paper
- Maslak, P. G., Dao, T., Bernal, Y., Chanel, S. M., Zhang, R., Frattini, M., Rosenblat, T., Jurcic, J. G., Brentjens, R. J., Arcila, M. E., Rampal, R., Park, J. H., Douer, D., Katz, L., Sarlis, N., Tallman, M. S., & Scheinberg, D. A. (2018). Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2017014175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.